Seres Therapeutics Inc (MCRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has a cash flow conversion efficiency ratio of -0.648x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.39 Million) by net assets ($34.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Seres Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Seres Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Seres Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seres Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Seres Therapeutics Inc (MCRB) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JP Morgan Global Growth & Income PLC
LSE:JGGI
|
0.004x |
|
Uangel
KO:072130
|
0.044x |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
0.195x |
|
Very Good Tour Co. Ltd
KQ:094850
|
-0.035x |
|
UNIQUE
KLSE:0257
|
0.049x |
|
Universal Textile Co Ltd
TW:1445
|
0.037x |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
N/A |
|
Honmyue Enterprise Co Ltd
TW:1474
|
0.029x |
Annual Cash Flow Conversion Efficiency for Seres Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2025. View MCRB stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.22 Million | $1.12 Million | 0.025x | +100.23% |
| 2024-12-31 | $13.78 Million | $-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | $-44.86 Million | $-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | $10.78 Million | $-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | $131.51 Million | $6.69 Million | 0.051x | +109.49% |
| 2020-12-31 | $174.75 Million | $-93.61 Million | -0.536x | -133.83% |
| 2019-12-31 | $-48.32 Million | $-76.52 Million | 1.583x | +21.04% |
| 2018-12-31 | $-48.05 Million | $-62.85 Million | 1.308x | +205.14% |
| 2017-12-31 | $60.70 Million | $-75.52 Million | -1.244x | -475.73% |
| 2016-12-31 | $132.63 Million | $43.92 Million | 0.331x | +266.53% |
| 2015-12-31 | $205.39 Million | $-40.84 Million | -0.199x | -151.30% |
| 2014-12-31 | $-26.72 Million | $-10.36 Million | 0.388x | +104.60% |
| 2013-12-31 | $631.00K | $-5.32 Million | -8.433x | -1733.56% |
| 2012-12-31 | $6.36 Million | $-2.92 Million | -0.460x | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more